Menu Search
Equities

DarioHealth Corp

LS1P:BER

DarioHealth Corp

Actions
  • Price (EUR)0.80
  • Today's Change0.02 / 2.56%
  • Shares traded1.03k
  • 1 Year change-13.98%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 16:42 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

DarioHealth Corp. is a global digital therapeutics (DTx) company. The Company operates at the intersection of life sciences, behavioral science, and software technology to deliver seamlessly integrated and highly engaging digital therapeutic interventions. Its platform and suite of solutions delivers personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. Its products include Dario Blood Pressure Monitoring System and Dario Blood Glucose Monitoring Starter Kit. Dario Blood Glucose Monitoring Starter Kit is a pocket-sized smartphone glucometer that manages diabetes in one ultra-compact device. Dario Blood Pressure Monitoring System is a blood pressure monitoring system used to measure blood pressure, which allows to store all its user readings in the Dario App. Its Dario mobile app is a complete, cloud-based solution for personal chronic condition management.

  • Revenue in USD (TTM)23.05m
  • Net income in USD-44.23m
  • Incorporated2011
  • Employees249.00
  • Location
    DarioHealth Corp322 W 57Th St. #33BNEW YORK 10019United StatesUSA
  • Phone+1 (646) 665-4667
  • Fax+1 (845) 818-3588
  • Websitehttps://shop.mydario.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		DRIO:NAQ since
announced		Transaction
value
Twill IncDeal completed15 Feb 202415 Feb 2024Deal completed-58.92%35.50m
Data delayed at least 15 minutes, as of Nov 22 2024 16:51 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.